Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein

Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search.